297 related articles for article (PubMed ID: 31609057)
1. Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.
McCormick N; Wallace ZS; Sacks CA; Hsu J; Choi HK
Arthritis Rheumatol; 2020 Feb; 72(2):234-241. PubMed ID: 31609057
[TBL] [Abstract][Full Text] [Related]
2. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
4. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis.
Dalal DS; Zhang T; Shireman TI
Semin Arthritis Rheum; 2020 Oct; 50(5):822-826. PubMed ID: 32896694
[TBL] [Abstract][Full Text] [Related]
5. Role of Specialty Drugs in Rising Drug Prices for Medicare Part D.
Hayford TB
JAMA Health Forum; 2024 May; 5(5):e241188. PubMed ID: 38787543
[TBL] [Abstract][Full Text] [Related]
6. Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.
Berkemeier F; Whaley C; Robinson JC
J Manag Care Spec Pharm; 2019 Dec; 25(12):1310-1317. PubMed ID: 31778624
[TBL] [Abstract][Full Text] [Related]
7. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
8. Estimates of Medicaid and Non-Medicaid Net Prices of Top-Selling Brand-name Drugs Incorporating Best Price Rebates, 2015 to 2019.
Clemans-Cope L; Epstein M; Banthin J; Kesselheim AS; Hwang TJ
JAMA Health Forum; 2023 Jan; 4(1):e225012. PubMed ID: 36637815
[TBL] [Abstract][Full Text] [Related]
9. Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends.
Atzinger CB; Guo JJ
Am Health Drug Benefits; 2017 Feb; 10(1):27-36. PubMed ID: 28465766
[TBL] [Abstract][Full Text] [Related]
10. Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Dickson S
JAMA Netw Open; 2020 Sep; 3(9):e2016388. PubMed ID: 32915237
[TBL] [Abstract][Full Text] [Related]
11. Spending on and Use of Clinician-Administered Drugs in Medicare.
Hyland MF; Sachs RM; Robillard L; Hayford TB; Bai G
JAMA Health Forum; 2023 Sep; 4(9):e232941. PubMed ID: 37682554
[TBL] [Abstract][Full Text] [Related]
12. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
13. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
Rome BN; Patel AN; Kesselheim AS
Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
[TBL] [Abstract][Full Text] [Related]
14. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
15. ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
Bian B; Kelton CM; Guo JJ; Wigle PR
J Manag Care Pharm; 2010; 16(9):671-9. PubMed ID: 21067253
[TBL] [Abstract][Full Text] [Related]
16. A decade of increases in Medicare Part B pharmaceutical spending: what are the drivers?
San-Juan-Rodriguez A; Gellad WF; Shrank WH; Good CB; Hernandez I
J Manag Care Spec Pharm; 2021 May; 27(5):565-573. PubMed ID: 33908276
[No Abstract] [Full Text] [Related]
17. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
18. Association between physician adoption of a new oral anti-diabetic medication and Medicare and Medicaid drug spending.
Metes ID; Xue L; Chang CH; Huskamp HA; Gellad WF; Lo-Ciganic WH; Choudhry NK; Richards-Shubik S; Guclu H; Donohue JM
BMC Health Serv Res; 2019 Oct; 19(1):703. PubMed ID: 31619229
[TBL] [Abstract][Full Text] [Related]
19. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
